Análisis de la acción Moderna Inc (MRNA)MRNAModerna Inc

Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Moderna is currently not a strong buy due to recent negative catalysts and mixed financial performance. The stock is priced at $137.99, with a significant recent drop of 6% following a $2.6 billion convertible notes offering, raising concerns about financing. Additionally, the forward P/E ratio is 23.04, suggesting that the stock is relatively expensive compared to its earnings potential. However, the stock has shown a remarkable year-to-date change of +347.15%, indicating strong past performance. The main risk is the recent insider selling trend, which has increased by 437.15% over the last quarter, suggesting a lack of confidence from insiders.